Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 11/20 | 1.00 |
| ▸ | MAT2A | P31153 | 4/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670286 | 0.96 | ENPP2 (0.92) | ENPP2MAT2APTGDR2AKR1B1 | |
| SCHEMBL671278 | 0.94 | ENPP2 (0.88) | ENPP2MAT2APTGDR2AKR1B1RORC | |
| SCHEMBL671600 | 0.93 | ENPP2 (0.86) | ENPP2MAT2APTGDR2AKR1B1 | |
| SCHEMBL671727 | 0.90 | ENPP2 (0.81) | ENPP2PTGDR2AKR1B1 | |
| SCHEMBL672736 | 0.90 | ENPP2 (0.80) | ENPP2MAT2APTGDR2AKR1B1 | |
| SCHEMBL670399 | 0.89 | ENPP2 (0.80) | ENPP2MAT2APTGDR2AKR1B1 | |
| SCHEMBL672129 | 0.89 | ENPP2 (0.80) | ENPP2MAT2APTGDR2AKR1B1 | |
| SCHEMBL672256 | 0.89 | ENPP2 (1.00) | ENPP2MAT2APTGDR2AKR1B1 | |
| SCHEMBL671493 | 0.87 | ENPP2 (0.77) | ENPP2MAT2APTGDR2AKR1B1 | |
| SCHEMBL670514 | 0.87 | ENPP2 (0.77) | ENPP2MAT2APTGDR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103201262-B | Autotaxin inhibitors and application thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2016-06-01 | — | — | CN | claimed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | claimed |
| EP-2606031-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-06-26 | — | — | EP | claimed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | claimed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | claimed |
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2606031-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2606031-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| CN-103201262-B | Autotaxin inhibitors and application thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2016-06-01 | — | — | CN | disclosed |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2606031-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885MAT2A 3074/4885PTGDR2 4411/4885 |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, SERPINE1 | ENPP2 1/4885MAT2A 3074/4885PTGDR2 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.